Contact Sales

-22nd September 2011

Mirada Medical Showcases Latest Imaging Solutions at ECCO, Efficiently Unites Cancer Treatment Team

Mirada Medical (Oxford, UK) will be introducing their Casemeeting software at the European Cancer Organization (ECCO) conference being held September 24-26 in Stockholm, Sweden. The conference brings together the European Society for Medical Oncology (ESMO) and the European Society for Radiation Oncology (ESTRO) to form the European Multidisciplinary Cancer Congress (ECCO). Casemeeting is the company’s latest innovative software-based solution for multidisciplinary cancer care.

When integrated with Mirada’s suite of products for diagnostic oncology, medical oncology and radiation oncology, Casemeeting promotes improved collaboration by supporting seamless and efficient communication of detailed information across the entire multidisciplinary cancer treatment team. Casemeeting uniquely allows collaborators to efficiently store, organize and present image based patient information at multidisciplinary team meetings. “The focus on multidisciplinary oncology care at ECCO is an ideal setting for demonstrating Casemeeting’’, stated Hugh Bettesworth, Mirada Medical’s CEO. ‘’Mirada has become well respected for its powerful technology solutions for individual disciplines. Now, Casemeeting fulfills our commitment to allow the individual disciplines to collaborate with one another through the effective communication of detailed and relevant case knowledge, particularly via the multidisciplinary meeting.” Mirada Medical will demonstrate its entire product suite at ECCO.

For radiation therapy planning, the company will highlight workflows which automate complex tasks such as: image registration, dose summation, atlas-based contouring and automatic deformable transfer of contours from previous plan to the current plan. Mirada’s radiation oncology products also support the full integration of PET and MRI into the planning process, as well as workflows for adaptive radiation therapy planning. For the medical oncologist, the company will show advanced multi-modal and multi-timepoint treatment response assessment where the clinical user is able to generate a quantified response report using all of the available patient images regardless of the time span over which the treatment has been carried out.

For diagnostic oncology, Mirada will demonstrate the latest version of its XD3 multi-modality reading application. XD3 may be used to analyse CT images together with PET, MRI or SPECT in a single reading workflow. It also includes enhanced support for advanced tri-modal fusion of MRI with PET-CT. The software supports standardised treatment response protocols such as RECIST and PERCIST making XD3 ideally suited for clinical trials.